- Home
- TCRT vs PTIX Comparison
TCRT vs PTIX Comparison
Compare TCRT & PTIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TCRT
- PTIX
- Stock Information
- Founded
- TCRT 1998
- PTIX 1994
- Country
- TCRT United States
- PTIX United States
- Employees
- TCRT N/A
- PTIX N/A
- Industry
- TCRT Biotechnology: Pharmaceutical Preparations
- PTIX Biotechnology: Pharmaceutical Preparations
- Sector
- TCRT Health Care
- PTIX Health Care
- Exchange
- TCRT Nasdaq
- PTIX Nasdaq
- Market Cap
- TCRT 2.5M
- PTIX 2.0M
- IPO Year
- TCRT N/A
- PTIX 2016
- Fundamental
- Price
- TCRT $3.08
- PTIX $0.49
- Analyst Decision
- TCRT
- PTIX
- Analyst Count
- TCRT 0
- PTIX 0
- Target Price
- TCRT N/A
- PTIX N/A
- AVG Volume (30 Days)
- TCRT 946.1K
- PTIX 324.0K
- Earning Date
- TCRT 05-14-2025
- PTIX 05-14-2025
- Dividend Yield
- TCRT N/A
- PTIX N/A
- EPS Growth
- TCRT N/A
- PTIX N/A
- EPS
- TCRT N/A
- PTIX N/A
- Revenue
- TCRT $10,000.00
- PTIX N/A
- Revenue This Year
- TCRT $5,680,500.00
- PTIX N/A
- Revenue Next Year
- TCRT N/A
- PTIX N/A
- P/E Ratio
- TCRT N/A
- PTIX N/A
- Revenue Growth
- TCRT 100.00
- PTIX N/A
- 52 Week Low
- TCRT $1.31
- PTIX $0.18
- 52 Week High
- TCRT $18.50
- PTIX $1.87
- Technical
- Relative Strength Index (RSI)
- TCRT 85.08
- PTIX 67.76
- Support Level
- TCRT $1.31
- PTIX $0.18
- Resistance Level
- TCRT $1.60
- PTIX $0.28
- Average True Range (ATR)
- TCRT 0.27
- PTIX 0.04
- MACD
- TCRT 0.16
- PTIX 0.01
- Stochastic Oscillator
- TCRT 87.12
- PTIX 62.39
About TCRT Alaunos Therapeutics Inc.
Alaunos Therapeutics Inc is a clinical-stage cellular immuno-oncology company dedicated to the treatment of solid tumors through adoptive TCR-T cell therapy. It strikes cancer at its core by engineering cell therapies that target Neoantigens arising from genomic mutations.
About PTIX Protagenic Therapeutics Inc.
Protagenic Therapeutics Inc is a biopharmaceutical company focused on the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. It provides treatments for mood, anxiety, depression, and neurodegenerative disorders by using peptide-based and brain-active therapeutics. The company's lead compound, PT00114, is a synthetic form of Teneurin Carboxy-terminal Associated Peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. It has also created a portfolio of novel neuropeptides that are in various stages of development and preclinical evaluation for the treatment of mood disorders.